Serono Rebif Blocked By Orphan Exclusivity, FDA Says, But Timing Is Unclear

Serono has been informed by FDA that approval of its multiple sclerosis therapy Rebif is blocked by the orphan drug exclusivity of both Berlex' Betaseron and Biogen's Avonex, but has not been given a date for when that exclusivity will expire.